Andrzej Tysarowski

Dr. Andrzej Tysarowski


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AZAgnieszka Zając
Agnieszka Zając
SKSylwia Kopeć
Sylwia Kopeć
BSBARTLOMIEJ SZOSTAKOWSKI
BARTLOMIEJ SZOSTAKOWSKI
Mateusz Jacek SpałekMateusz Jacek Spałek
Mateusz Jacek Spałek
MFMichal Fiedorowicz
Michal Fiedorowicz
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
Chondrosarcoma (CHS) is the second most common primary malignant bone sarcoma. Overall survival and prognosis of this tumor are various and often extreme, depending on histological grade and tumor subtype. CHS treatment is difficult, and surgery remains still the gold standard due to the resistance of this tumor to other therapeutic options. Considering the role of differentiation of CHS subtypes and the need to develop new treatment strategies, in this review, we introduced a multidisciplinary characterization of CHS from its pathology to therapies. We described the morphology of each subtype with the role of immunohistochemical markers in diagnostics of CHS. We also summarized the most frequently mutated genes and genome regions with altered pathways involved in the pathology of this tumor. Subsequently, we discussed imaging methods and the role of currently used therapies, including surgery and the limitations of chemo and radiotherapy. Finally, in this review, we presented novel targeted therapies, including those at ongoing clinical trials, which can be a potential future target in designing new therapeutics for patients with CHS.

27 July 2017 in Biomarkers in Medicine
Verified
Journal Article
Open access
GKGeorge Kafatos
George Kafatos
DNDaniela Niepel
Daniela Niepel
KLKimberley Lowe
Kimberley Lowe
SJSophie Jenkins-Anderson
Sophie Jenkins-Anderson
HWHal Westhead
Hal Westhead
JTJörg Trojan
Jörg Trojan
Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Materials & methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8–48.5%); ranging from 33.7% (95% CI: 28.4–39.3%) to 54.1% (95% CI: 51.7–56.5%) between sources. Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

22 March 2011 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
PKPaulina Kober
Paulina Kober
MBMateusz Bujko
Mateusz Bujko
JOJanusz Olędzki
Janusz Olędzki
ATAndrzej Tysarowski
Andrzej Tysarowski
JSJanusz A. Siedlecki
Janusz A. Siedlecki

8 May 2014 in Oncology Letters
Verified
Journal Article
Open access
PDF file
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
AGAleksandra Gos
Aleksandra Gos
MJMonika Jurkowska
Monika Jurkowska
TŚTomasz Świtaj
Tomasz Świtaj
WDWirginiusz Dziewirski
Wirginiusz Dziewirski
JSJanusz A. Siedlecki
Janusz A. Siedlecki
The aim of the present study was to evaluate the frequency and type of oncogenic v‑raf murine sarcoma viral oncogene homolog B1 (BRAF)/neuroblastoma RAS viral (v‑ras) oncogene homolog (NRAS) mutations in cutaneous melanoma with clinically detected nodal metastases (stage IIIB and C) in relation to clinicopathological features and outcome. The clinicopathological data of 250 patients following therapeutic lymphadenectomy (LND) between 1995 and 2010, as well as BRAF/NRAS mutational status in corresponding nodal metastases, were analyzed. The median follow‑up time was 53 months. BRAF mutations were detected in 154 (62%) cases (141 p.V600E, nine p.V600K and four others) and mutually exclusive NRAS mutations were detected in 42 (17%) cases. The presence of a BRAF mutation was found to correlate with patients of a younger age. The five‑year overall survival (OS) rate was 33 and 43% for LND and primary tumor excision, respectively, and the five‑year disease‑free survival (DFS) rate for LND was 25%. No correlation was identified between BRAF/NRAS mutational status and RFS or OS (calculated from the date of the LND and primary tumor excision); for BRAF‑ and NRAS‑mutated melanoma, the prognosis was the same for patients with wild‑type (WT) melanoma. The important factors which had a negative impact on OS and DFS were as follows: Male gender, >1 metastatic lymph node and extracapsular extension of nodal metastases. The interval between the diagnosis of the initial melanoma to regional nodal metastasis (median, 10 months) was not significantly different between BRAF‑mutant and ‑WT patients. Our largest comprehensive molecular analysis of clinical stage III melanoma revealed that BRAF and NRAS mutational status is not a prognostic marker in stage III melanoma patients with macroscopic nodal involvement, but may have implications for potential adjuvant therapy.

7 April 2014 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MBMateusz Bujko
Mateusz Bujko
PKPaulina Kober
Paulina Kober
ATAndrzej Tysarowski
Andrzej Tysarowski
EMEwa Matyja
Ewa Matyja
TMTomasz Mandat
Tomasz Mandat
JSJanusz Aleksander Siedlecki
Janusz Aleksander Siedlecki
Meningiomas are among the most frequent intracranial tumors. Treatment involves surgical resection with optional subsequent radiotherapy for high‑grade meningiomas or radiosurgery following incomplete tumor removal. At present, no pharmacological agents are used as treatment. The use of targeted therapies has been considered, and specific therapies, including anti‑EGFR treatment, have been clinically tested. The experience from the treatment of various types of cancers shows that patient outcome depends on the mutational status of particular molecules, including epithelial growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α (PIK3CA). Therefore, the aim of the present study was to assess the occurrence and potential use of these markers in patients with meningioma. In total, 55 formalin‑fixed, paraffin‑embedded meningioma samples were subjected to genomic sequencing of EGFR (exons 18‑21), KRAS (exon 1), BRAF (exon 15) and PI3K (exons 9, 20). No mutations were identified in EGFR, KRAS or BRAF. Point mutations in PIK3CA were revealed in the samples of two patients with atypical and anaplastic meningiomas. Although these mutations appear to be rare, this result, along with previously reported findings, indicates that the PI3K/protein kinase B pathway may serve as a more reasonable molecular target for meningioma than EGFR.

21 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OSOlga Stanowska
Olga Stanowska
OKOlga Izabela Kuczkiewicz-Siemion
Olga Izabela Kuczkiewicz-Siemion
MDMalgorzata Debowska
Malgorzata Debowska
WOWojciech P. Olszewski
Wojciech P. Olszewski
AJAgnieszka Irena Jagiello-Gruszfeld
Agnieszka Irena Jagiello-Gruszfeld
MPMonika Prochorec-Sobieszek
Monika Prochorec-Sobieszek
Triple negative breast cancer (TNBC) is typically a high-grade breast cancer with poorest clinical outcome despite available treatment modalities with chemo-, immuno- and radiotherapy. The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor closely related to programmed death ligand 1 (PD-L1) expressed on T lymphocytes modulating antitumor immunity. Immune-checkpoint inhibitors (ICI) are showing promising results in a subset of breast cancer patients in both neo- and adjuvant settings. Pathologic complete response (pCR) after neoadjuvant treatment was found to be associated with better prognosis. We analyzed the prognostic and predictive significance of PD-L1 (SP142 assay) immunohistochemical expression on TNBC patients’ samples as illustrated by pCR with regard to its relation to treatment regimen, stage, BRCA mutational status and outcome. Furthermore, we analyzed a few other clinicopathological parameters such as age, TILs and proliferation index. The study highlighted a positive role of PD-L1 evaluation for personalized pCR probability assessment. Although considerable research was made on comparison of PD-L1 level in TNBC with different patient parameters, to our best knowledge, the relation of PD-L1 status to pCR while taking treatment regimen and stage into consideration was so far not investigated.